Type 2 diabetes mellitus with diabetic nephropathy
ICD-10 E11.21 is a billable code used to indicate a diagnosis of type 2 diabetes mellitus with diabetic nephropathy.
E11.21 represents Type 2 diabetes mellitus with diabetic nephropathy, a serious complication of diabetes characterized by damage to the kidneys due to prolonged high blood sugar levels. In patients with Type 2 diabetes, nephropathy can develop over time, often leading to chronic kidney disease (CKD) and potentially end-stage renal disease (ESRD). The condition is typically diagnosed through the presence of albumin in the urine (albuminuria) and a decline in glomerular filtration rate (GFR). Management of diabetic nephropathy involves strict glycemic control, often monitored through HbA1c levels, which should ideally be maintained below 7% to reduce the risk of complications. Insulin therapy may be required for some patients, especially if oral medications are insufficient. Regular monitoring of kidney function and blood pressure is crucial, as hypertension is a common comorbidity that can exacerbate nephropathy. Early detection and intervention are key to slowing the progression of kidney damage and improving patient outcomes.
Detailed records of diabetes management, including medication adjustments and HbA1c levels.
Patients presenting with uncontrolled diabetes and signs of nephropathy.
Ensure that nephropathy is documented as a complication of diabetes.
Comprehensive assessment of kidney function, including GFR and urine tests.
Patients with CKD secondary to diabetes requiring dialysis or transplant evaluation.
Document the stage of kidney disease and its relation to diabetes.
Used to monitor glycemic control in patients with diabetes.
Document the date of the test and results.
Endocrinologists should ensure regular HbA1c testing is part of the management plan.
HbA1c levels are crucial for assessing long-term glycemic control in patients with Type 2 diabetes and diabetic nephropathy. Maintaining an HbA1c below 7% can help prevent further kidney damage and other complications.
Patients with E11.21 should have their kidney function monitored at least annually, including assessments of GFR and urine albumin levels, to detect any progression of nephropathy.
